Drugs / MAGE-12 peptide vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00020267 | Jul 2000 → ? | bone cancer, breast cancer, colon carcinoma, lung cancer +5 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-12 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00020267 ↗ |
| Route | Subcutaneous | “Patients receive MAGE-12 peptide vaccine emulsified in Montanide ISA-51 adjuvant subcutaneously (SC) weekly for 4 doses.” NCT00020267 ↗ |